FFA
ASBPW

Farther Finance Advisors’s Aspire Biopharma Warrant ASBPW Stock Holding History

Farther Finance Advisors’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$1 – 4691
2025
Q1 		$1 Buy
+10
New +$1 ﹤0.01% 4260

Other funds holding ASBPW

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

Farther Finance Advisors's ASBPW Position: Q2 2025 in Review

Farther Finance Advisors sold out of Aspire Biopharma Warrant (ASBPW) in Q2 2025, closing a stake of 10 shares — an estimated $1 sold.

Farther Finance Advisors first reported a position in ASBPW in Q1 2025 and held it in 1 quarter. The position peaked at $1 in Q1 2025. 29 funds tracked by Wall St. Rank hold ASBPW as of Q2 2025.

  • Farther Finance Advisors reported no remaining Aspire Biopharma Warrant position as of Q2 2025 after selling out during the quarter.
  • Farther Finance Advisors sold 10 Aspire Biopharma Warrant shares in Q2 2025, an estimated $1.
  • Farther Finance Advisors first reported a position in Aspire Biopharma Warrant in Q1 2025 and held it in 1 quarter.
  • Farther Finance Advisors's Aspire Biopharma Warrant position peaked at $1 in Q1 2025.
  • 29 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2025.

Based on Farther Finance Advisors's 13F filing for Q2 2025, filed 11 Jul 2025.